[ad_1]
On the 9th (local time) at the Calletano Heredia University Clinical Research Center in Lima, Peru, a doctor inoculates the arm of a clinical trial volunteer with a new vaccine against coronavirus infection (Corona 19) produced by Sinofam , China. [이미지출처=연합뉴스]
According to foreign media such as AFP on the 11th (local time), this clinical trial was finally stopped because a participant could not move his arm due to ‘Guillanin-Barré syndrome’.
Guillain-Barré syndrome refers to inflammation of the peripheral nerves, causing pain and paralysis in the extremities.
Hermann Málaga, chief researcher at Peru’s National Institute of Health, told a press conference on the day that “one of the test participants showed neurological symptoms corresponding to Guillain-Barré syndrome,” he said.
Initially, in Peru, a clinical trial of a sinofam vaccine was conducted in about 12,000 people. It was originally scheduled to publish the results of the clinical trial this week.
Currently, the Sinopam vaccine is undergoing clinical trials in about 60,000 people in Peru, Argentina, Russia and Saudi Arabia. Sinoparm said, “There have been more than 1 million people who have been vaccinated so far and there have been no side effects,” and announced a plan to provide 1 billion doses by next year.
Internal reporter Choi Eun-young [email protected]
